Long Term Care Journal
Friday, June 21, 2019
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women - FDA Press Releases
FDA approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
from FDA Press Releases RSS Feed http://bit.ly/2ISSd3m
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment